DiaMedica, Sanomune deal

DiaMedica signed a non-binding letter of intent to acquire Sanomune in a stock deal. Sanomune will receive about 12.8 million common shares of DiaMedica valued at C$7.9 million (US$7.5 million) based on DiaMedica's close of C$0.62 on Nov. 30, the day before the deal was announced. Sanomune's lead compound is SAN-61. The mechanism of action and timeline for the compound to start Phase II testing for Alzheimer's disease are undisclosed.. ...